Skip to main content
Glecaprevir, pibrentasvir effective in those with HCV, liver disease

An integrated analysis of nine trials in the Phase II and III stages assessed glecaprevir and pibrentasvir as a treatment for chronic hepatitis C genotype 1 to 6 infections and indicated that the regimen was safe and effective in those with compensated liver disease as well as those with stage IV or stage V chronic kidney disease. Details of the analysis were published in the journal Clinical Infectious Diseases.

Full Story: